Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium

Molecular Pharmaceutics

Volumn 11, Issue 6, 2014, Pages 1808-1822

  Conti, Denise S ^a,b   Brewer, Daniel ^a   Grashik, Jordan ^a   Avasarala, Sumant ^a   Da Rocha, Sandro R P ^a  

^a Wayne State University   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

alveolar epithelium; gene silencing; PAMAM dendrimers; pressurized metered dose inhalers (pMDIs); pulmonary siRNA delivery; siRNA dendriplexes

Indexed keywords

DENDRIMER; ENHANCED GREEN FLUORESCENT PROTEIN; HEPARIN; MANNITOL; NANOCARRIER; POLYAMIDOAMINE; RIBONUCLEASE; RIBONUCLEASE INHIBITOR; SMALL INTERFERING RNA; AEROSOL; DRUG CARRIER; GREEN FLUORESCENT PROTEIN; NANOPARTICLE; POLYAMINE;

AEROSOL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DISPERSION; ENZYME DEGRADATION; GEL ELECTROPHORESIS; GENE SILENCING; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; INHALER; LONG TERM EXPOSURE; LUNG ALVEOLUS EPITHELIUM; MTS ASSAY; NONVIRAL GENE DELIVERY SYSTEM; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RIBONUCLEASE PROTECTION ASSAY; SEDIMENTATION RATE; ADMINISTRATION AND DOSAGE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EPITHELIUM CELL; LUNG; MEDICINAL CHEMISTRY; PARTICLE SIZE; PROCEDURES; RESPIRATORY TRACT MUCOSA; TUMOR CELL LINE;

AEROSOLS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; GREEN FLUORESCENT PROTEINS; HUMANS; LUNG; NANOPARTICLES; PARTICLE SIZE; POLYAMINES; RESPIRATORY MUCOSA; RNA, SMALL INTERFERING;

EID: 84901808611     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4006358     Document Type: Article

References (79)

1. Pecot, C. V.; Calin, G. A.; Coleman, R. L.; Lopez-Berestein, G.; Sood, A. K. RNA interference in the clinic: Challenges and future directions Nat. Rev. Cancer 2011, 11 (1) 59-67
2. Siomi, H.; Siomi, M. C. On the road to reading the RNA-interference code Nature 2009, 457 (7228) 396-404
3. Arima, H.; Yoshimatsu, A.; Ikeda, H.; Ohyama, A.; Motoyama, K.; Higashi, T.; Tsuchiya, A.; Niidome, T.; Katayama, Y.; Hattori, K.; Takeuchi, T. Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier Mol. Pharmaceutics 2012, 9 (9) 2591-2604
4. Lam, J. K.-W.; Liang, W.; Chan, H.-K. Pulmonary delivery of therapeutic siRNA Adv. Drug Delivery Rev. 2012, 64 (1) 1-15
5. Gao, K.; Huang, L. Nonviral methods for siRNA delivery Mol. Pharmaceutics 2008, 6 (3) 651-658
6. Taratula, O.; Garbuzenko, O. B.; Chen, A. M.; Minko, T. Innovative strategy for treatment of lung cancer: Targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA J. Drug Targeting 2011, 19 (10) 900-914
7. Caci, E.; Melani, R.; Pedemonte, N.; Yueksekdag, G.; Ravazzolo, R.; Rosenecker, J.; Galietta, L. J.; Zegarra-Moran, O. Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA Am. J. Respir. Cell Mol. Biol. 2009, 40 (2) 211-216
8. Séguin, R. M.; Ferrari, N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease Expert Opin. Invest. Drugs 2009, 18 (10) 1505-1517
9. Zamora, M. R.; Budev, M.; Rolfe, M.; Gottlieb, J.; Humar, A.; DeVincenzo, J.; Vaishnaw, A.; Cehelsky, J.; Albert, G.; Nochur, S.; Gollob, J. A.; Glanville, A. R. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus Am. J. Respir. Crit. Care Med. 2011, 183 (4) 531-538
10. Li, B.-j.; Tang, Q.; Cheng, D.; Qin, C.; Xie, F. Y.; Wei, Q.; Xu, J.; Liu, Y.; Zheng, B.-j.; Woodle, M. C.; Zhong, N.; Lu, P. Y. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque Nat. Med. 2005, 11 (9) 944-951
11. Fujita, Y.; Takeshita, F.; Kuwano, K.; Ochiya, T. RNAi therapeutic platforms for lung diseases Pharmaceuticals 2013, 6 (2) 223-250
12. Merkel, O. M.; Zheng, M.; Debus, H.; Kissel, T. Pulmonary gene delivery using polymeric nonviral vectors Bioconjugate Chem. 2011, 23 (1) 3-20
13. Heiden, T. C. K.; Dengler, E.; Kao, W. J.; Heideman, W.; Peterson, R. E. Developmental toxicity of low generation PAMAM dendrimers in zebrafish Toxicol. Appl. Pharmacol. 2007, 225 (1) 70-79
14. Paleos, C. M.; Tsiourvas, D.; Sideratou, Z. Molecular engineering of dendritic polymers and their application as drug and gene delivery systems Mol. Pharmaceutics 2007, 4 (2) 169-188
15. Albertazzi, L.; Storti, B.; Marchetti, L.; Beltram, F. Delivery and subcellular targeting of dendrimer-based fluorescent pH sensors in living cells J. Am. Chem. Soc. 2010, 132 (51) 18158-18167
16. Kesharwani, P.; Gajbhiye, V.; Jain, N. K. A review of nanocarriers for the delivery of small interfering RNA Biomaterials 2012, 33 (29) 7138-7150
17. Shakhbazau, A.; Isayenka, I.; Kartel, N.; Goncharova, N.; Seviaryn, I.; Kosmacheva, S.; Potapnev, M.; Shcharbin, D.; Bryszewska, M. Transfection efficiencies of PAMAM dendrimers correlate inversely with their hydrophobicity Int. J. Pharm. 2010, 383 (1-2) 228-235
18. Zhou, J.; Wu, J.; Hafdi, N.; Behr, J.-P.; Erbacher, P.; Peng, L. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing Chem. Commun. 2006, 2006 (22) 2362
19. Movassaghian, S.; Moghimi, H. R.; Shirazi, F. H.; Koshkaryev, A.; Trivedi, M. S.; Torchilin, V. P. Efficient down-regulation of PKC-α gene expression in A549 lung cancer cells mediated by antisense oligodeoxynucleotides in dendrosomes Int. J. Pharm. 2013, 441 (1-2) 82-91
20. Durcan, N.; Murphy, C.; Cryan, S.-A. Inhalable siRNA: Potential as a therapeutic agent in the lungs Mol. Pharmaceutics 2008, 5 (4) 559-566
21. Zhang, J.; Wu, L.; Chan, H.-K.; Watanabe, W. Formation, characterization, and fate of inhaled drug nanoparticles Adv. Drug Delivery Rev. 2011, 63 (6) 441-455
22. Foster, K. A.; Oster, C. G.; Mayer, M. M.; Avery, M. L.; Audus, K. L. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism Exp. Cell Res. 1998, 243 (2) 359-366
23. Tang, Y.; Li, Y.-B.; Wang, B.; Lin, R.-Y.; van Dongen, M.; Zurcher, D. M.; Gu, X.-Y.; Banaszak Holl, M. M.; Liu, G.; Qi, R. Efficient in vitro siRNA delivery and intramuscular gene silencing using PEG-modified PAMAM dendrimers Mol. Pharmaceutics 2012, 9 (6) 1812-1821
24. Mishra, M. K.; Gérard, H. C.; Whittum-Hudson, J. A.; Hudson, A. P.; Kannan, R. M. Dendrimer-enabled modulation of gene expression in Chlamydia trachomatis Mol. Pharmaceutics 2012, 9, 413-421
25. Molecular Probes-Invitrogen Detection Technologies. Protocol for Quant-iT PicoGreen ® dsDNA Reagent and Kits; 2008; MP 07581, 1-7; http://www.lifetechnologies.com/us/en/home/brands/molecular-probes.html.
26. Bedi, D.; Musacchio, T.; Fagbohun, O. A.; Gillespie, J. W.; Deinnocentes, P.; Bird, R. C.; Bookbinder, L.; Torchilin, V. P.; Petrenko, V. A. Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes Nanomed. Nanotechnol. Biol. Med. 2011, 7 (3) 315-323
27. Rasband, W. S. ImageJ; U. S. National Institutes of Health: Bethesda, Maryland, USA. http://imagej.nih.gov/ij/ 1997-2012.
28. Nomani, A.; Haririan, I.; Rahimnia, R.; Fouladdel, S.; Gazori, T.; Dinarvand, R.; Omidi, Y.; Azizi, E. Physicochemical and biological properties of self-assembled antisense/poly(amidoamine) dendrimer nanoparticles: The effect of dendrimer generation and charge ratio Int. J. Nanomed. 2010, 5, 359
29. Lavignac, N.; Nicholls, J. L.; Ferruti, P.; Duncan, R. Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker Macromol. Biosci. 2009, 9 (5) 480-487
30. Invitrogen by Life Technologies. Protocol for Lipofectamine 2000 2006; pp 1-4.
31. Promega Corporation. Protocol for CellTiter 96® aqueous non-radioactive cell proliferation assay, Part # TB169 2009; pp 1-16.
32. Promega Corporation. Protocol for TransFast Transfection Reagent, Part # TB260 2009; pp 1-17.
33. Conti, D. S.; Bharatwaj, B.; Brewer, D.; da Rocha, S. R. P. Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation J. Controlled Release 2012, 157 (3) 406-417
34. Rogueda, P. G. A. HPFP, a model propellant for pMDIs Drug Dev. Ind. Pharm. 2003, 29 (1) 39-49
35. U.S. Department of Health and Human Services. Guidance for Industry-Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products-chemistry, manufacturing, and controls documentation; Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER): Rockville, MD 1998, 62
36. Bharatwaj, B.; Wu, L.; Whittum-Hudson, J. A.; da Rocha, S. R. P. The potential for the noninvasive delivery of polymeric nanocarriers using propellant-based inhalers in the treatment of Chlamydial respiratory infections Biomaterials 2010, 31 (28) 7376-7385
37. Antipina, M. N.; Gainutdinov, R. V.; Rachnyanskaya, A. A.; Tolstikhina, A. L.; Yurova, T. V.; Khomutov, G. B. Studies of nanoscale structural ordering in planar DNA complexes with amphiphilic mono- and polycations Surf. Sci. 2003, 532-535, 1025-1033
38. Jensen, L. B.; Pavan, G. M.; Kasimova, M. R.; Rutherford, S.; Danani, A.; Nielsen, H. M.; Foged, C. Elucidating the molecular mechanism of PAMAM-siRNA dendriplex self-assembly: Effect of dendrimer charge density Int. J. Pharm. 2011, 416 (2) 410-418
39. Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides Mol. Pharmaceutics 2009, 6 (3) 686-695
40. Liu, Y.; Bryantsev, V. S.; Diallo, M. S.; Goddard Iii, W. A. PAMAM dendrimers undergo pH responsive conformational changes without swelling J. Am. Chem. Soc. 2009, 131 (8) 2798-2799
41. De Rosa, G.; Quaglia, F.; Bochot, A.; Ungaro, F.; Fattal, E. Long-term release and improved intracellular penetration of oligonucleotide- polyethylenimine complexes entrapped in biodegradable microspheres Biomacromolecules 2003, 4 (3) 529-536
42. Kolhe, P.; Misra, E.; Kannan, R. M.; Kannan, S.; Lieh-Lai, M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers Int. J. Pharm. 2003, 259 (1-2) 143-160
43. Maiti, P. K.; Çaǧin, T.; Lin, S.-T.; Goddard, W. A. Effect of solvent and pH on the structure of PAMAM dendrimers Macromolecules 2005, 38 (3) 979-991
44. Jain, K.; Kesharwani, P.; Gupta, U.; Jain, N. K. Dendrimer toxicity: Let's meet the challenge Int. J. Pharm. 2010, 394 (1-2) 122-142
45. Jevprasesphant, R.; Penny, J.; Jalal, R.; Attwood, D.; McKeown, N. B.; D'Emanuele, A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers Int. J. Pharm. 2003, 252 (1-2) 263-266
46. Li, C.; Liu, H.; Sun, Y.; Wang, H.; Guo, F.; Rao, S.; Deng, J.; Zhang, Y.; Miao, Y.; Guo, C.; Meng, J.; Chen, X.; Li, L.; Li, D.; Xu, H.; Wang, H.; Li, B.; Jiang, C. PAMAM nanoparticles promote acute lung injury by inducing autophagic cell death through the Akt-TSC2-mTOR signaling pathway J. Mol. Cell Biol. 2009, 1 (1) 37-45
47. Kannan, S.; Kolhe, P.; Raykova, V.; Glibatec, M.; Kannan, R. M.; Lieh-Lai, M.; Bassett, D. Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells J. Biomater. Sci., Polym. Ed. 2004, 15, 311-330
48. Biswas, S.; Deshpande, P. P.; Navarro, G.; Dodwadkar, N. S.; Torchilin, V. P. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery Biomaterials 2013, 34 (4) 1289-1301
49. Pavan, G. M.; Posocco, P.; Tagliabue, A.; Maly, M.; Malek, A.; Danani, A.; Ragg, E.; Catapano, C. V.; Pricl, S. PAMAM dendrimers for siRNA delivery: Computational and experimental insights Chem.-Eur. J. 2010, 16 (26) 7781-7795
50. Kim, Y.; Klutz, A. M.; Jacobson, K. A. Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: Synthesis, characterization, and evaluation of cytotoxicity Bioconjugate Chem. 2008, 19 (8) 1660-1672
51. Perez, A. P.; Romero, E. L.; Morilla, M. J. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents Int. J. Pharm. 2009, 380 (1-2) 189-200
52. Wang, X.-L.; Xu, R.; Lu, Z.-R. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery J. Controlled Release 2009, 134 (3) 207-213
53. Liu, X.; Liu, C.; Laurini, E.; Posocco, P.; Pricl, S.; Qu, F.; Rocchi, P.; Peng, L. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer Mol. Pharmaceutics 2012, 9 (3) 470-481
54. Li, S.-D.; Chen, Y.-C.; Hackett, M. J.; Huang, L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles Mol. Ther. 2007, 16 (1) 163-169
55. Zintchenko, A.; Philipp, A.; Dehshahri, A.; Wagner, E. Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity Bioconjugate Chem. 2008, 19 (7) 1448-1455
56. Gu, S.; Rossi, J. J. Uncoupling of RNAi from active translation in mammalian cells RNA 2005, 11 (1) 38-44
57. Merkel, O. M.; Mintzer, M. A.; Librizzi, D.; Samsonova, O.; Dicke, T.; Sproat, B.; Garn, H.; Barth, P. J.; Simanek, E. E.; Kissel, T. Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: The effects of peripheral groups and core structure on biological activity Mol. Pharmaceutics 2010, 7 (4) 969-983
58. Zheng, M.; Librizzi, D.; Kiliç, A.; Liu, Y.; Renz, H.; Merkel, O. M.; Kissel, T. Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers Biomaterials 2012, 33 (27) 6551-6558
59. Tschuch, C.; Schulz, A.; Pscherer, A.; Werft, W.; Benner, A.; Hotz-Wagenblatt, A.; Barrionuevo, L.; Lichter, P.; Mertens, D. Off-target effects of siRNA specific for GFP BMC Mol. Biol. 2008, 9 (1) 60
60. Naito, Y.; Yamada, T.; Matsumiya, T.; Ui-Tei, K.; Saigo, K.; Morishita, S. dsCheck: Highly sensitive off-target search software for double-stranded RNA-mediated RNA interference Nucleic Acids Res. 2005, 33 (web server) W589-W591
61. Merkel, O. M.; Beyerle, A.; Beckmann, B. M.; Zheng, M.; Hartmann, R. K.; Stöger, T.; Kissel, T. H. Polymer-related off-target effects in non-viral siRNA delivery Biomaterials 2011, 32 (9) 2388-2398
62. Akhtar, S.; Benter, I. Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity Adv. Drug Delivery Rev. 2007, 59 (2-3) 164-182
63. Patton, J. S.; Byron, P. R. Inhaling medicines: Delivering drugs to the body through the lungs Nat. Rev. Drug Discovery 2007, 6 (1) 67-74
64. Peguin, R. P. S.; Wu, L.; da Rocha, S. R. P. The ester group: How hydrofluoroalkane-philic is it? Langmuir 2007, 23 (16) 8291-8294
65. Wu, L.; Bharatwaj, B.; Panyam, J.; da Rocha, S. Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants Pharm. Res. 2008, 25 (2) 289-301
66. Kho, K.; Hadinoto, K. Effects of excipient formulation on the morphology and aqueous re-dispersibility of dry-powder silica nano-aggregates Colloids Surf. A 2010, 359 (1-3) 71-81
67. Young, P. M.; Adi, H.; Patel, T.; Law, K.; Rogueda, P.; Traini, D. The influence of micronised particulates on the aerosolisation properties of pressurised metered dose inhalers J. Aerosol Sci. 2009, 40 (4) 324-337
68. Wu, L.; Peguin, R. P. S.; da Rocha, S. R. P. Understanding solvation in hydrofluoroalkanes: Ab Initio calculations and chemical force microscopy J. Phys. Chem. B 2007, 111 (28) 8096-8104
69. Elversson, J.; Millqvist-Fureby, A. Particle size and density in spray drying-Effects of carbohydrate properties J. Pharm. Sci. 2005, 94 (9) 2049-2060
70. Mitchell, J. P.; Nagel, M. W.; Wiersema, K. J.; Doyle, C. C. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: Comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 aerodynamic particle sizer aerosol spectrometer AAPS PharmSciTech 2003, 4 (4) 1-9
71. McCabe, J. C.; Koppenhagen, F.; Blair, J.; Zeng, X.-M. ProAir® HFA delivers warmer, lower-impact, longer-duration plumes containing higher fine particle dose than Ventolin® HFA J. Aerosol Med. Pulm. Drug Delivery 2012, 25 (2) 104-109
72. LeBelle, M.; Pike, R. K.; Graham, S. J.; Ormsby, E. D.; Bogard, H. A. Metered-dose inhalers I: Drug content and particle size distribution of beclomethasone dipropionate J. Pharm. Biomed. Anal. 1996, 14 (7) 793-800
73. Yang, W.; Peters, J. I.; Williams, R. O., III. Inhaled nanoparticles-A current review Int. J. Pharm. 2008, 356 (1-2) 239-247
74. Crowder, T. M.; Rosati, J. A.; Schroeter, J. D.; Hickey, A. J.; Martonen, T. B. Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development Pharm. Res. 2002, 19 (3) 239-245
75. Gu, J.; Su, S.; Li, Y.; He, Q.; Shi, J. Hydrophilic mesoporous carbon nanoparticles as carriers for sustained release of hydrophobic anti-cancer drugs Chem. Commun. 2011, 47 (7) 2101-2103
76. Burnett, J. C.; Rossi, J. J.; Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials Biotechnol. J. 2011, 6 (9) 1130-1146
77. Jensen, D. M. K.; Cun, D.; Maltesen, M. J.; Frokjaer, S.; Nielsen, H. M.; Foged, C. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation J. Controlled Release 2010, 142 (1) 138-145
78. Jensen, D. K.; Jensen, L. B.; Koocheki, S.; Bengtson, L.; Cun, D.; Nielsen, H. M.; Foged, C. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA J. Controlled Release 2012, 157 (1) 141-148
79. Huth, S.; Schmidt, C.; Rudolph, C.; Rosenecker, J. Analysis of the stability and functionality of siRNA after nebulization of siRNA polyplexes Mol. Ther. 2006, 13 (S1) S272-S272